ME 401

Drug Profile

ME 401

Alternative Names: Kinase program - MEI Pharma; ME401; PWT-143

Latest Information Update: 15 Nov 2016

Price : $50

At a glance

  • Originator Pathway Therapeutics
  • Developer MEI Pharma
  • Class Antineoplastics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Follicular lymphoma; Haematological malignancies

Most Recent Events

  • 01 Sep 2016 Phase-I clinical trials in Chronic lymphocytic leukaemia (Second-line therapy or greater) in USA (unspecified route) (NCT02914938)
  • 01 Sep 2016 Phase-I clinical trials in Follicular lymphoma (Second-line therapy or greater) in USA (unspecified route) (NCT02914938)
  • 20 Apr 2016 Pharmacokinetics and adverse events data from a phase I trial in Healthy volunteers presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top